Global Duchenne Muscular Dystrophy Therapeutics Market Primary and Secondary Research, Segmentation, Projections, SWOT Analysis and Forecast by 2022

OrbisResearch.com has published new research report on "Global Duchenne Muscular Dystrophy Therapeutics Market By Drug (Translarna, Emflaza, EXONDYS 51), By Therapeutic Approach (Steroid Therapy, Exon Skipping, Mutation Suppression) Forecast to 2022" to its database.

Dallas, United States - July 17, 2017 /MarketersMedia/ —

Duchenne Muscular Dystrophy (DMD) is a fatal genetic disorders diagnosed in children around the world. DMD is often referred to as orphan or rare diseases, as it affects only a small portion of the population, approximately 1 in every 3,500 live male births. However, various treatment approaches are available now-a-days that can inhibit progression of the disease. Amongst, the most attractive are molecular based therapies, such as mutation suppression or exon skipping. Moreover, there are many more drugs in various phases of clinical trials, which will help in the growth of this market.

Browse the report: http://www.orbisresearch.com/reports/index/global-duchenne-muscular-dystrophy-therapeutics-market-by-drug-translarna-emflaza-exondys-51-by-therapeutic-approach-steroid-therapy-exon-skipping-mutation-suppression-forecast-to-2022

According to RNCOS’ new research report “Global Duchenne Muscular Dystrophy Therapeutics Market By Drug (Translarna, Emflaza, EXONDYS 51), By Therapeutic Approach (Steroid Therapy, Exon Skipping, Mutation Suppression) Forecast to 2022”, the Duchenne Muscular Dystrophy Therapeutics industry can possibly turn into a multi-million dollar industry by the end of 2022, as new products, particularly those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth.

The Duchenne Muscular Dystrophy Therapeutics market has very few marketed products, such as Emflaza, Translarna, and EXONDYS 51. The market is majorly in the research phase, from which most of its revenue is generated. Therefore, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the Duchenne Muscular Dystrophy market, such as phases, geographies, etc. The report also provides the sales of major marketed Duchenne Muscular Dystrophy products, and the list of the products in clinical/pre-clinical research along with their clinical phases.

Request a sample of the report: http://www.orbisresearch.com/contacts/request-sample/333580

The report provides a detailed analysis of the current and future market scenario of the global Duchenne Muscular Dystrophy Therapeutics market. RNCOS, in its report, further covers insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global Duchenne Muscular Dystrophy Therapeutics market. The report also provides insights regarding the strategies adopted by the players from 2015 to 2017 for enhancing their market share.
The segmentation of Duchenne Muscular Dystrophy Therapeutics market has been done on the basis of different therapeutic approaches and geographical regions. Primarily, the Duchenne Muscular Dystrophy Therapeutics market is dominated by mutation suppression and exon skipping approach, with several companies and academic institutions focusing on potential for each of these treatments.

Based on the geography, the market is divided into three regions, namely - North America, Europe, and Asia Pacific. There are several treatments for DMD that are approved or under review in the European Union or are expected to be under review by regulatory agencies in the near future. This is a major reason for the dominant position of Europe in the Duchenne Muscular Dystrophy market.

Buy the report@http://www.orbisresearch.com/contact/purchase/333580

The later part of the report discusses some of the prominent players in the global Duchenne Muscular Dystrophy Therapeutics market. The market share analysis of these players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their business segments, product portfolios and recent developments. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.

Major Points From The Table Of Contents:
Analyst View
Research Methodology
Duchenne Muscular Dystrophy (DMD): An Overview
Market Dynamics
Global Duchenne Muscular Dystrophy Therapeutics Market Outlook 2022
Approved Drugs
Market Segmentation by Therapeutic Approach
Market Segmentation by Geography
Clinical Trial Assessment & Pipeline Analysis
Industry Trends and Developments
Strategic Alliances
Competitive Landscape
Key Player Analysis

List of Figures:
Figure 5-1: Global - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022
Figure 6-1: Global - Sales of EXONDYS 51 (Million US$), 2016
Figure 6-2: Global - Sales of Translarna (Million US$), 2014-2017
Figure 7-1: Global - Duchenne Muscular Dystrophy Therapeutics Market by Therapeutic Approach (%), 2016
Figure 7-2: Global - Mutation Suppression Market for Duchenne Muscular Dystrophy (Million US$), 2016-2022
Figure 7-3: Global - Steroid Therapy Market for Duchenne Muscular Dystrophy (Million US$), 2016-2022
Figure 7-4: Global - Exon Skipping Therapy Market for Duchenne Muscular Dystrophy (Million US$), 2016-2022
Figure 8-1: Global - Duchenne Muscular Dystrophy Therapeutics Market by Geography (%), 2016
Figure 8-2: Europe - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022
Figure 8-3: North America - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022
Figure 8-4: Asia Pacific - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022

List of Tables:
Table 4-1: Grants for Duchenne Muscular Dystrophy
Table 4-2: Per-Patient Annual Costs of DMD, 2012
Table 6-1: Ongoing Trials for Emflaza
Table 6-2: Ongoing Trials for EXONDYS 51
Table 6-3: Ongoing Trials for Translarna
Table 7-1: Disease-Modifying Therapies for Duchenne Muscular Dystrophy
Table 9-1: Global Duchenne Muscular Dystrophy Therapeutics Pipeline

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Info:
Name: Hector Costello
Email: sales@orbisresearch.com
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A.
Phone: +1 (214) 884-6817

Source URL: http://marketersmedia.com/global-duchenne-muscular-dystrophy-therapeutics-market-primary-and-secondary-research-segmentation-projections-swot-analysis-and-forecast-by-2022/217967

For more information, please visit http://www.orbisresearch.com/reports/index/global-duchenne-muscular-dystrophy-therapeutics-market-by-drug-translarna-emflaza-exondys-51-by-therapeutic-approach-steroid-therapy-exon-skipping-mutation-suppression-forecast-to-2022

Source: MarketersMedia

Release ID: 217967

Latest News

Rare birds, wildflowers: 'Secret garden' opens after century

Jul 28, 2017

TRUCKEE, Calif. — Pink and yellow wildflowers burst from a lush bed of grass hidden from public view for more than a century. Towering trees and snow-capped mountains encircle the wild meadow, beckoning visitors to a largely untouched piece of California's Sierra Nevada. Conservation groups bought the land in Lower Carpenter Valley north of Lake Tahoe and are opening it for tours. It contains rare carnivorous plants and threatened birds and serves as a migration corridor for other species. Bird songs and the gurgle of a serpentine creek provide the soundtrack in the meadow less than 8 miles from noisy...

Indonesia orangutan sanctuary says villagers encroaching

Jul 28, 2017

JAKARTA, Indonesia — A conservation group says nearly a fifth of the forest in an orangutan sanctuary on the Indonesian part of Borneo has been taken over by people, threatening efforts to rehabilitate the critically endangered great apes for release into the wild. People thought to have migrated from other parts of Indonesia have occupied part of the sanctuary, cut down trees and planted crops including palm oil, Borneo Orangutan Survival Foundation spokesman Nico Hermanu said Thursday. The human activities are near a "forest school" where more than 20 orangutans live semi-independently and learn how to find food, build nests...

Warming to worsen dead zones, algae blooms choking US waters

Jul 28, 2017

WASHINGTON — Projected increases in rain from global warming could further choke U.S. waterways with fertilizer runoff that trigger dead zones and massive algae blooms, a new study said. If greenhouse gas emissions keep rising, more and heavier rain will increase nitrogen flowing into lakes, rivers and bays by about 19 percent by the end of the century, according to a study in Thursday's journal Science . While that may not sound like much, many coastal areas are already heavily loaded with nitrogen. Researchers calculated that an extra 860,000 tons of nitrogen yearly will wash into American waterways by century's...

Prosecutor: Martin Shkreli repeatedly lied to investors

Jul 28, 2017

NEW YORK — A prosecutor at the securities fraud trial of Martin Shkreli says the former pharmaceutical CEO scammed investors in a pair of failed hedge funds. Prosecutor Alixandra Smith told a jury in closing arguments on Thursday that Shkreli repeatedly lied to investors about how much money was in one of the funds as it was going under. She said he assured investors that he was managing $40 million at a time when there as only a few hundred dollars in his firm's brokerage account. In a recent Facebook post, the 34-year-old defendant calls the case "bogus." Before his...

Businesses, cities cashing in on total solar eclipse crowds

Jul 28, 2017

BARTLETT, Tenn. — Millions of eyes will be fixed on the sky when a total solar eclipse crosses the U.S. in August. It's likely many of them will be safely behind the special glasses churned out by a Tennessee company. American Paper Optics ramped up production for this year's eclipse and expects to make 50 million paper and plastic eclipse glasses. The company in suburban Memphis is one of many businesses — hotels, campgrounds and stores — taking advantage of the total solar eclipse. The total eclipse will move across the country from Oregon to South Carolina on Aug. 21....

Search

Recent Discovery will take you to the captivating developments in science, technology, and the universe around us. We deliver to you the latest news, theories, and developments in the world of science.

Contact us: sales@recentdiscovery.com

Trending News

ScienceAgricultural ScienceArchaeologyAstronomy Press